ICH Q11

ICH Q11 — 'Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological / Biological Entities)' — is the harmonised ICH guideline that defines what regulators expect in the drug-substance (API) section of the eCTD Module 3.2.S of a marketing-authorisation dossier. Adopted at Step 4 in May 2012, it replaced the patchwork of regional drug-substance development guidance that preceded it and gave industry + regulators a single framework for both chemical entities (small molecules) and biotechnological / biological entities (monoclonal antibodies, recombinant proteins, fusion proteins, vaccines, gene + cell therapies).

Q11 has two operational layers. The first is the development-science layer: how the drug substance was developed, what the manufacturing process is, how the control strategy was derived, what the impurity profile looks like, what characterisation supports the structure + identity. The second is the dossier-content layer: what goes into each section of eCTD Module 3.2.S (S.1 General Information, S.2 Manufacture, S.3 Characterisation, S.4 Control of Drug Substance, S.5 Reference Standards, S.6 Container Closure System, S.7 Stability). Q11 §6 specifically defines the structure of S.2.6 — the development summary — which is the single most-read section by regulators during initial assessment + post-approval review.

The August 2017 Q&A document supplemented Q11 with the operational answers to the question that came to dominate inspection + assessment practice: how do you select + justify starting materials? The Q&A provides eight specific Q&As covering the criteria, the documentation expectations, the linkage between Q11 + Q7, and the regulatory consequences of starting-material designation. The Q&A is treated as part of the Q11 standard in regulatory practice.

Q11 explicitly covers both chemical entities and biotechnological / biological entities. The structural framework is common across both classes, but Q11 includes class-specific sections recognising the differences:

• Chemical entities — synthetic small molecules, semi-synthetic compounds, extracted natural products processed by chemical or physical operations. Q11 §3 covers chemical-entity-specific development considerations including the process flow + synthetic route, impurity origin + control, polymorph + crystal form selection.
• Biotechnological / biological entities — proteins + polypeptides produced by recombinant or non-recombinant cell culture expression systems, including monoclonal antibodies. Q11 §4 covers biological-entity-specific development considerations including expression system, cell substrate, manufacturing process for the drug substance (cell culture / fermentation through harvest, purification + viral safety + drug-substance formulation).

Q11 does not cover whole blood + plasma + plasma derivatives (covered by product-specific WHO + regional guidance), vaccines (covered by WHO TRS + regional guidance, with substantial overlap), and gene / cell therapies (covered by ICH Q5A-D for biologicals + product-specific ATMP guidance in the EU + the FDA cell + gene therapy framework). However, the Q11 framework — and especially the control-strategy + starting-materials thinking — is routinely applied in addition to the product-specific framework for these out-of-scope products.

Q11 §5 defines two approaches to drug-substance development that map directly onto Q8(R2) thinking for drug products:

• Traditional approach — process parameters set on the basis of fixed ranges around point-of-validation values; minor / moderate changes typically require regulatory submission (variation / supplement); the control strategy is largely a list of fixed parameters + acceptance criteria.
• Enhanced (QbD) approach — systematic application of prior knowledge + risk assessment + design-of-experiments to define a design space (a multidimensional combination of input variables + process parameters demonstrated to provide assurance of quality); regulatory flexibility within the design space; the control strategy explicitly derives from CQAs + CPPs + scientific understanding of the process.

Most modern drug-substance dossiers — particularly for innovator biologics + complex small molecules — adopt an enhanced approach for the most critical process steps and a traditional approach for the rest. The hybrid is acceptable provided the rationale is documented in S.2.6. The enhanced approach pays back in lifecycle management: ICH Q12 Established Conditions, post-approval change-management protocols (PACMPs), and PLCM (Product Lifecycle Management) documents all leverage QbD-derived process understanding to reduce post-approval regulatory burden.

Q11 §5.1.1 + the 2017 Q&A define the framework for selecting + justifying API starting materials. The starting-material designation is the single most consequential decision in the dossier because it sets the boundary at which Q7 GMP begins. Steps upstream of the starting material are subject to good documentation + chemistry practice but not full Q7 GMP; steps downstream are full Q7 with all the documentation + validation + change-control rigour that entails.

The Q11 + Q&A criteria for selecting a starting material:

• It is a synthetic precursor incorporated as a significant structural fragment into the drug substance — purely catalytic / temporary / solubility-mediating species do not qualify.
• It is a well-characterised, isolated + purified substance with defined chemical properties + structure.
• Critical structural fragments — particularly chiral centres — should generally be introduced from the starting material or controlled within the GMP region of the process.
• The synthetic route from starting material to drug substance should include sufficient chemical transformations to provide assurance of purity + impurity profile (the EMA reflection paper expects 'a sufficient number of steps' — typically interpreted as multiple chemical transformations beyond simple salt formation or final purification).
• Sufficient information on the manufacture of the starting material is provided in the regulatory dossier to allow regulator review of the upstream process even though it is outside Q7 GMP.
• Impurities arising upstream that could carry into the drug substance must be characterised + controlled — designating a starting material too far downstream does not avoid the requirement to understand + control upstream-derived impurities.

The failure modes are well-catalogued:

Defending the starting-material selection in the dossier is a structured exercise: (1) draw the full synthetic route from commercially-sourced raw material to API; (2) identify the proposed starting material on the route; (3) justify the position against each of the Q11 + Q&A criteria with reference to scientific evidence; (4) describe the manufacturing process for the starting material in S.2.3 (Control of Materials); (5) describe the impurity profile + controls in S.3.2 (Impurities); (6) document the rationale in S.2.6 (Development) and cross-reference S.2.3 + S.3.2.

Q11 §5.2 + §6 codify how the control strategy for the drug substance is derived from product + process understanding:

1. Define the quality target product profile (QTPP) — relevant for drug substances primarily through linkage to the QTPP of the drug product.
2. Identify CQAs — physical, chemical, biological + microbiological properties / characteristics of the drug substance that should be within an appropriate limit / range / distribution to ensure desired product quality.
3. Link CQAs to upstream process attributes — material attributes of inputs, process parameters at each step.
4. Assess risk — using ICH Q9(R1) techniques (FMEA / FTA / RRF / HACCP-style mapping) to identify which material attributes + process parameters are critical (CPPs) and how they affect CQAs.
5. Develop process understanding — through experimental studies (often DoE for the enhanced approach) to define functional relationships between CPPs + CQAs.
6. Define the control strategy — the planned set of controls derived from current process + product understanding, including controls on material attributes, process parameters, manufacturing procedures + in-process controls, finished-product specifications, monitoring + control of CQAs.

The control strategy described in S.2.6 must be internally consistent with S.2.2 (Description of Manufacturing Process + Process Controls), S.2.3 (Control of Materials), S.2.4 (Controls of Critical Steps + Intermediates), S.2.5 (Process Validation + Evaluation) and S.4 (Control of Drug Substance). Inconsistencies between sections are common deficiency-letter triggers.

Q11 § 6 + ICH M4Q define the dossier content for drug substance:

• Manufacturing process — cell culture / fermentation (upstream) + harvest, recovery, purification, viral clearance (downstream), drug-substance formulation; viral-clearance validation per ICH Q5A(R2) (2022 revision) is a dossier-critical artefact for mammalian-derived biologics.
• Cell substrate + cell banks — master + working cell banks characterised per ICH Q5A / Q5B / Q5D; the cell bank is the biological equivalent of an API starting material.
• Process changes during development + comparability — ICH Q5E governs comparability assessment for process changes including site transfers, scale-up, expression-system changes; pre-/post-change comparability often the gating activity for post-approval change.
• Characterisation — extensive physicochemical + biological characterisation per ICH Q6B; higher-order structure, post-translational modifications, biological activity, immunogenicity-relevant attributes.
• Specifications — typically include identity, purity (including process-related + product-related impurities), potency (bioassay), quantity, general tests; often more specifications than small molecule because more attributes must be controlled.
• Reference standards — establishment + qualification of in-house reference standards aligned with the WHO International Standard where one exists (for monoclonal antibodies + cytokines, often there is one).

• Starting-material justification thin or absent — proposed starting material is essentially an intermediate; insufficient chemical transformations downstream of the starting material.
• Critical chiral centre not introduced from the starting material + not adequately controlled by downstream chemistry.
• S.2.6 development summary is a process-flow description without development history, design-space discussion, or control-strategy rationale.
• Inconsistency between S.2.2 / S.2.3 / S.2.4 / S.2.5 / S.2.6 + S.4 — the dossier reads as if multiple authors wrote sections in isolation without cross-checking.
• Impurity profile in S.3.2 incomplete — potential impurities from upstream chemistry omitted; qualification thresholds per ICH Q3A / Q3C not applied.
• Process validation in S.2.5 described as a one-shot commitment without lifecycle approach (FDA 2011 Stage 1 / 2 / 3) or CPV plan.
• Comparability for biologics weak — Q5E protocol absent or executed without pre-defined acceptance criteria.
• Cell bank documentation incomplete — characterisation per Q5A / Q5B / Q5D missing elements; sub-cultivation history not tracked.
• Viral clearance validation per Q5A(R2) missing modules — particularly for parvovirus / circovirus clearance after the 2022 R2 revision tightened expectations.
• Reference standards not adequately characterised or not adequately linked to international standards where one exists.
• Specifications in S.4 not justified — acceptance criteria appear without batch-data rationale + clinical-experience tie-back.
• Stability data in S.7 do not yet support the proposed retest / shelf life — at-risk filings without adequate post-approval stability commitment.
• Post-approval lifecycle plan absent — Q12 Established Conditions + PACMP not defined despite the QbD process understanding being present.
• Knowledge management gap — development knowledge documented at filing but not effectively transferred to the commercial site for ongoing reference.
• Data integrity gaps in development data — at-risk filings particularly when development was done at a CDMO without robust GxP-aligned data governance.

• Starting-material justification completeness score (per Q11 + 2017 Q&A criteria).
• Dossier cross-reference integrity — % of CQA mentions consistent across S.2.2 / S.2.3 / S.2.4 / S.2.6 / S.4.
• Critical-step + critical-intermediate count per drug substance + control coverage.
• Development-knowledge file completeness — DoE protocols, design-space evidence, control-strategy rationale, scale-up history.
• Comparability assessment count + outcome per process change (biologics).
• Viral-clearance validation module coverage (biologics) per Q5A(R2).
• Impurity-qualification coverage — % of identified / potential impurities qualified per Q3A / Q3C thresholds.
• Stability data coverage at filing — months × condition vs proposed shelf life.
• Q12 Established Conditions count + PACMP coverage for high-frequency changes.
• Post-filing deficiency-letter count per drug-substance dossier section.
• Knowledge-transfer completeness at tech-transfer between development + commercial sites.
• S.2.6 development-summary regulator-reading-time proxy — typically 8-20 pages well-written vs 50+ pages of unstructured process-flow narrative.

V5 Ultimate treats Q11 as the development-science overlay for the process-industry profile, with API + biologic drug-substance manufacturing as first-class workspace types. Every drug substance has a Q11 development register: the QTPP linkage, the CQA list with CPP linkage, the synthetic-route or biological-process diagram with the starting-material gate marked + justified against the Q11 + 2017 Q&A criteria, the control-strategy rationale, the impurity profile (actual + potential, with qualification status), the comparability assessments per Q5E for biologics, the viral-clearance validation modules per Q5A(R2).

Dossier assembly is structured around eCTD M4Q section structure. S.2.6 development summaries are assembled from the development register with cross-references auto-checked against S.2.2 / S.2.3 / S.2.4 / S.2.5 / S.4 so that CQA + CPP + control mentions remain internally consistent. Starting-material justifications are versioned + cross-referenced from S.2.3 + S.3.2 + S.2.6; designation changes require formal regulatory-impact assessment routed through change-control with ICH Q9 risk input. Cell-bank records per Q5A / Q5B / Q5D are managed under formal life-cycle control with sub-cultivation history + characterisation evidence.

Q11 + Q12 are wired together: Established Conditions are explicit fields on the drug-substance record; PACMP-eligible changes are tagged + routed differently from full-variation changes; the post-approval lifecycle plan is a living document that surfaces commitments + change-management opportunities at management review. Knowledge management per Q10 is closed at the development → commercial tech-transfer boundary with structured tacit-knowledge capture + the development register becoming the commercial-site reference. Every Q11 artefact carries audit-trail evidence per 21 CFR 11 / Annex 11 and renders into the regulatory submission pack on demand.